Literature DB >> 22236785

Outcomes of Boston keratoprosthesis implantation for failed keratoplasty after keratolimbal allograft.

Joshua H Hou1, Jose de la Cruz, Ali R Djalilian.   

Abstract

PURPOSE: To evaluate factors that contribute to keratoplasty failure after keratolimbal allograft (KLAL) and report the outcomes of Boston keratoprosthesis type I (KPro) as salvage therapy.
METHODS: Retrospective noncomparative case series of 7 eyes in 7 consecutive patients with ocular surface disease and limbal stem cell deficiency treated with KPro after failed KLAL. Mechanisms of graft failure, KPro device retention rate, and preoperative and postoperative best-corrected visual acuities were studied.
RESULTS: In the studied cohort, keratoplasty graft failure occurred at an average of 9.9 months (range, 1-17 months) after KLAL. Among the 7 eyes reviewed, 4 had tube shunts, 3 of which contributed directly to endothelial graft failure. One eye failed due to fungal keratitis, 1 eye failed due to immune-mediated endothelial rejection, and 2 eyes failed due to recurrent surface disease. During an average follow-up of 585 days (19.5 months) after KPro, best-corrected visual acuity improved from a median of counting fingers CF@2ft (range, hand motions to 20/400) to a median of 20/400 (range, CF@3ft to 20/25). There was 85.7% (6 of 7) retention of implanted devices at the last follow-up, with 1 eye requiring repeat KPro for corneal melt and implant extrusion after abrupt cessation of immunosuppression.
CONCLUSIONS: Despite successful KLAL outcomes and systemic immunosuppression, patients who undergo ocular surface reconstruction with KLAL are still at risk for subsequent keratoplasty failure. Keratoprosthesis is a viable salvage therapy for visual rehabilitation in these patients. Adequate immunosuppression is important in postoperative management of these patients.

Entities:  

Mesh:

Year:  2012        PMID: 22236785     DOI: 10.1097/ICO.0b013e31823e2ac6

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  11 in total

1.  Management strategies for persistent epithelial defects of the cornea.

Authors:  Lee R Katzman; Bennie H Jeng
Journal:  Saudi J Ophthalmol       Date:  2014-07-02

2.  Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Boston Keratoprosthesis in Southern China: A Retrospective Study.

Authors:  Yuying Zhang; Zhancong Ou; Jin Zhou; Jiajie Zhai; Jianjun Gu; Jiaqi Chen
Journal:  Adv Ther       Date:  2020-05-20       Impact factor: 3.845

3.  Diagnostic criteria for limbal stem cell deficiency before surgical intervention-A systematic literature review and analysis.

Authors:  Qihua Le; Tulika Chauhan; Sophie X Deng
Journal:  Surv Ophthalmol       Date:  2019-07-02       Impact factor: 6.048

4.  Corneal inflammation after miniature keratoprosthesis implantation.

Authors:  Alja Crnej; Masahiro Omoto; Thomas H Dohlman; Claes H Dohlman; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-16       Impact factor: 4.799

Review 5.  Current and Upcoming Therapies for Ocular Surface Chemical Injuries.

Authors:  Alireza Baradaran-Rafii; Medi Eslani; Zeeshan Haq; Ebrahim Shirzadeh; Michael J Huvard; Ali R Djalilian
Journal:  Ocul Surf       Date:  2016-09-17       Impact factor: 5.033

Review 6.  The Ocular Surface and How It Can Influence the Outcomes of Keratoprosthesis.

Authors:  Sarah Moussa; Herbert Reitsamer; Josef Ruckhofer; Günther Grabner
Journal:  Curr Ophthalmol Rep       Date:  2016-11-05

7.  Long-Term Outcomes of Allogeneic Ocular Surface Reconstruction: Keratolimbal Allograft (KLAL) Followed by Penetrating Keratoplasty (PK).

Authors:  Katarzyna Krysik; Dariusz Dobrowolski; Dorota Tarnawska; Edward Wylegala; Anita Lyssek-Boroń
Journal:  J Ophthalmol       Date:  2020-04-14       Impact factor: 1.909

8.  Sputter Deposition of Titanium on Poly(Methyl Methacrylate) Enhances Corneal Biocompatibility.

Authors:  Sina Sharifi; Mohammad Mirazul Islam; Hannah Sharifi; Rakibul Islam; Per H Nilsson; Claes H Dohlman; Tom Eirik Mollnes; Eleftherios I Paschalis; James Chodosh
Journal:  Transl Vis Sci Technol       Date:  2020-12-23       Impact factor: 3.283

Review 9.  The ocular surface chemical burns.

Authors:  Medi Eslani; Alireza Baradaran-Rafii; Asadolah Movahedan; Ali R Djalilian
Journal:  J Ophthalmol       Date:  2014-07-01       Impact factor: 1.909

Review 10.  Limbal stem cell transplantation: current perspectives.

Authors:  Marwan Raymond Atallah; Sotiria Palioura; Victor L Perez; Guillermo Amescua
Journal:  Clin Ophthalmol       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.